Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.59 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.49 |
| ▸ | ANPEP | P15144 | 5/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.42 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707643 | 1.00 | MMP2 (0.59) | MMP2USP30ANPEPNR1H2KDM4E | |
| SCHEMBL12609045 | 0.95 | MMP2 (0.52) | MMP2USP30ANPEPNR1H2KDM4E | |
| SCHEMBL29548395 | 0.93 | USP30 (0.57) | MMP2USP30ANPEPNR1H2MEN1 | |
| SCHEMBL29548628 | 0.93 | MMP2 (0.52) | MMP2USP30ANPEPNR1H2KDM4E | |
| SCHEMBL3110842 | 0.91 | MMP2 (0.73) | MMP2USP30ANPEPNR1H2KDM4E | |
| SCHEMBL30476434 | 0.91 | MMP2 (0.57) | MMP2USP30ANPEPNR1H2KDM4E | |
| SCHEMBL6365330 | 0.91 | MMP2 (0.73) | MMP2USP30ANPEPNR1H2KDM4E | |
| SCHEMBL3110836 | 0.91 | MMP2 (0.73) | MMP2USP30ANPEPNR1H2KDM4E | |
| SCHEMBL14092130 | 0.90 | MMP2 (0.54) | MMP2USP30ANPEPNR1H2KDM4E | |
| SCHEMBL29548777 | 0.90 | MMP2 (0.49) | MMP2USP30ANPEPNR1H2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102753166-B | Tetrapeptide analogs, preparation method and use thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2014-10-15 | — | — | CN | disclosed |
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| WO-2011057477-A1 | TETRAPEPTIDE ANALOGS, PREPARATION METHOD AND USE THEREOF | 上海艾力斯医药科技有限公司 (CN) | 2011-05-19 | — | — | WO | disclosed |
| EP-1950199-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | MMP2 45/4885USP30 1808/4885ANPEP 16/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | MMP2 45/4885USP30 1808/4885ANPEP 16/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | MMP2 42/4885USP30 1818/4885ANPEP 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.